Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLL
Getting specific with myeloma therapy: selecting the right treatments
The pivotal ZUMA-1 trial for NHL
Biosimilars and the future of more affordable treatment for hematologic malignancies
Which treatments are currently available for relapsed and refractory myeloma treatment?